08Apr 2023
Challenging the status quo: Is it time to re-evaluate cisplatin dosing frequency in head and neck cancer?

Challenging the status quo: Is it time to re-evaluate cisplatin dosing frequency in head and neck cancer?

The article discusses the use of weekly cisplatin chemotherapy with radiotherapy compared to 3-weekly cisplatin chemotherapy with radiotherapy in treating locoregionally advanced head and neck cancer. The authors conducted a literature review and found evidence supporting the noninferiority of weekly cisplatin chemotherapy in both adjuvant and definitive settings. However, there is a lack of superiority trials in the existing literature. The article highlights the need for further research to conclusively determine the efficacy of weekly cisplatin chemotherapy in treating locoregionally advanced head and neck cancer.

  • #ent

Like

Save

Share